Patents by Inventor Jay R. Luly

Jay R. Luly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
    Patent number: 6548499
    Abstract: Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: April 15, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, David Thomas Connor, Jie Jack Li, Joseph Edwin Low, Jay R. Luly, Steven Robert Miller, Bruce David Roth, Bharat Kalidas Trivedi
  • Chemokine receptor antagonists and methods of use therefor
    Publication number: 20030045516
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
    Type: Application
    Filed: August 13, 2002
    Publication date: March 6, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Geraldine C. B. Harriman
  • Chemokine receptor antagonists and methods of use therefor
    Patent number: 6509346
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: and physiologically acceptable salts thereof.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: January 21, 2003
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Geraldine C. B. Harriman
  • Chemokine receptor antagonists and methods of use therefor
    Patent number: 6503926
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: and physiologically acceptable salts thereof.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: January 7, 2003
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Geraldine C. B. Harriman
  • Imidazolidine compounds
    Patent number: 6495569
    Abstract: Disclosed are novel compounds and a method of treating inflammatory diseases. The method comprises administering to an individual in need an effective amount of an imidazolidine compound represented by Structural Formula (I): and physiologically or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: December 17, 2002
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Rie Komatsu, Gregory J. LaRosa, Jay R. Luly
  • Chemokine receptor anagonists and methods of use therefor
    Publication number: 20020169155
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
    Type: Application
    Filed: November 21, 2001
    Publication date: November 14, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Geraldine C.B. Harriman, Kenneth G. Carson
  • CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
    Publication number: 20020161005
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
    Type: Application
    Filed: July 28, 1999
    Publication date: October 31, 2002
    Inventors: JAY R. LULY, YOSHISUKE NAKASATO, ETSUO OHSHIMA, HIROKI SONE, OSAMU KOTERA, GERALDINE C. B. HARRIMAN
  • Imidazolidine compounds
    Patent number: 6469002
    Abstract: Disclosed are novel compounds and a method of treating inflammatory diseases. The method comprises administering to an individual in need an effective amount of an imidazolidine compound represented by Structural Formula (I): and physiologically or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: October 22, 2002
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Rie Komatsu, Gregory J. LaRosa, Jay R. Luly
  • CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
    Publication number: 20020119973
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
    Type: Application
    Filed: July 28, 1999
    Publication date: August 29, 2002
    Inventors: JAY R. LULY, YOSHISUKE NAKASATO, ETSUO OHSHIMA, HIROKI SONE, OSAMU KOTERA, GERALDINE C.B. HARRIMAN
  • Chemokine receptor antagonists and methods of use therefor
    Patent number: 6433165
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by the following structural formula: and physiologically acceptable salts thereof.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: August 13, 2002
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima
  • Chemokine receptor antagonists and methods of use therefor
    Patent number: 6329385
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by the following structural formula: and physiologically acceptable salts thereof.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: December 11, 2001
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima
  • AZOLE INHIBITORS OF CYTOKINE PRODUCTION
    Publication number: 20010044445
    Abstract: Compounds having the formula 1
    Type: Application
    Filed: April 8, 1999
    Publication date: November 22, 2001
    Inventors: NWE Y. BAMAUNG, ANWER BASHA, STEVAN W. DJURIC, EARL J. GUBBINS, JAY R. LULY, NOAH P. TU, DAVID J. MADAR, USHA WARRIOR, PAUL E. WIEDEMAN, XUN ZHOU, RICHARD J. SCIOTTI, FRANK L. WAGENAAR
  • Chemokine receptor antagonists and methods of use therefor
    Patent number: 6288083
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by the following structural formula: and physiologically acceptable salts thereof.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: September 11, 2001
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima
  • Chemokine receptor antagonists and methods of use therefor
    Patent number: 6288084
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by the following structural formula: and physiologically acceptable salts thereof.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: September 11, 2001
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima
  • Glucocortiocoid-selective agents
    Patent number: 6166013
    Abstract: Compounds having Formula I ##STR1## are useful for modulating the glucocorticoid receptor in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula I and methods of treating immune, autoimmune, inflammatory, adrenal imbalance, cognitive and behavioral diseases in a mammal.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: December 26, 2000
    Assignee: Abbott Laboratories
    Inventors: Michael J. Coghlan, Jay R. Luly, Jeffrey M. Schkeryantz, Alan X. Wang
  • Macrocyclic amide and urea immunomodulators
    Patent number: 5731320
    Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and pharmaceutically-acceptable salts, esters, amides and prodrugs thereof, as well as pharmaceutical compositions containing the same, which possess immunosuppressive, antimicrobial, antifungal, antiviral, antiinflammatory and antiproliferative activity, as well as the ability to reverse chemotherapeutic drug resistance.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: March 24, 1998
    Assignee: Abbott Laboratories
    Inventors: Rolf Wagner, Jay R. Luly, Yat Sun Or
  • Macrocyclic immunomodulators
    Patent number: 5708002
    Abstract: Immunomodulatory macrocyclic compounds having the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein X is selected from one of the formulae ##STR2## as well as pharmaceutical compositions containing the same.
    Type: Grant
    Filed: October 23, 1996
    Date of Patent: January 13, 1998
    Assignee: Abbott Laboratories
    Inventors: Jay R. Luly, Megumi Kawai, Yat Sun Or, Paul Wiedeman, Rolf Wagner
  • Macrolide immunomodulators
    Patent number: 5672605
    Abstract: Novel macrolide compounds of the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, processes for the preparation of the compounds of the invention, intermediates useful in these processes, a pharmaceutical composition, and a method of treating immunomodulatory disorders are disclosed.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: September 30, 1997
    Assignee: Abbott Laboratories
    Inventors: Yat Sun Or, Jay R. Luly, Rolf Wagner
  • Anaphylatoxin receptor ligands containing lipophilic residues
    Patent number: 5663148
    Abstract: Oligopeptide compounds or oligopeptide analague compounds of the formula, A-B-D-E-G-J-L-M-N(R.sup.4)Arg-OH, which are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states, as well as anaphylatoxin receptor ligand compositions and a method for modulating anaphylatoxin activity.
    Type: Grant
    Filed: July 12, 1994
    Date of Patent: September 2, 1997
    Assignee: Abbott Laboratories
    Inventors: Yat Sun Or, Jay R. Luly
  • Marcrocyclic amide and urea immunomodulators
    Patent number: 5643918
    Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and pharmaceutically-acceptable salts, esters, amides and prodrugs thereof, as well as pharmaceutical compositions containing the same, which possess immunosuppressive, antimicrobial, antifungal, antiviral, antiinflammatory and antiproliferative activity, as well as the ability to reverse chemotherapeutic drug resistance.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: July 1, 1997
    Assignee: Abbott Laboratories
    Inventors: Rolf Wagner, Jay R. Luly, Yat Sun Or